The failure to discuss potential harms of more widespread testing in more than a general way is a significant omission in this story.
While we love the concept of this study, this release ignores the overall negative findings of the research, and instead highlights results from a small group of men within the study.
With some wording changes and a few more statistics, this pretty good story about aspirin for cancer prevention would have become demonstrably better.
This bare-bones report on a drug trial was probably aimed at investors — but will almost certainly reach consumers as well. We think both groups would be interested in the very high cost of this drug combination.